Literature DB >> 22274992

Immunosuppressive therapy in aplastic anemia.

Vineeta Gupta1, Akash Kumar, Vijai Tilak, Isha Saini, Baldev Bhatia.   

Abstract

OBJECTIVE: To assess the response to antithymocyte globulin based immunosuppressive therapy (IST) in pediatric patients with idiopathic aplastic anemia.
METHODS: Thirty patients (19 boys and 11 girls) with aplastic anemia received antithymocyte globulin and cyclosporine. Twenty-two patients had severe and 8 had very severe aplastic anemia.
RESULTS: Mean age of the patients was 9.19 ± 2.56 y. Three patients died within 1 mo of therapy, two due to sepsis and one due to intracranial hemorrhage. Twenty-seven patients were analyzed for response to therapy. Eight patients (29.7%) responded at 3 mo: 3 complete response (CR) and 5 partial response (PR). Six mo after the therapy, overall response (OR) was seen in 9/27 (33.3%), with one more patient in no response group achieving partial response. At 1 year, patients in CR maintained their status and 1 patient in PR group relapsed. He again achieved partial response with repeat course of ATG. Responders had significantly shorter duration of illness and higher absolute neutrophil count as compared to non responders to IST. None of the patients developed acute leukemia in the follow up.
CONCLUSIONS: The treatment of aplastic anemia in pediatric patients is a challenging task. One third of the patients achieved overall response which included both complete and partial response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22274992     DOI: 10.1007/s12098-012-0691-2

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  22 in total

1.  Selection of patients for bone marrow transplantation in severe aplastic anemia.

Authors:  B M Camitta; J M Rappeport; R Parkman; D G Nathan
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

2.  Guidelines for the diagnosis and management of acquired aplastic anaemia.

Authors:  J C W Marsh; S E Ball; P Darbyshire; E C Gordon-Smith; A J Keidan; A Martin; S R McCann; J Mercieca; D Oscier; A W W Roques; J A L Yin
Journal:  Br J Haematol       Date:  2003-12       Impact factor: 6.998

3.  Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO).

Authors:  A Bacigalupo; B Bruno; P Saracco; E Di Bona; A Locasciulli; F Locatelli; A Gabbas; C Dufour; W Arcese; G Testi; G Broccia; M Carotenuto; P Coser; T Barbui; P Leoni; A Ferster
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

Review 4.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young; Rodrigo T Calado; Phillip Scheinberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

5.  Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Authors:  E Di Bona; F Rodeghiero; B Bruno; A Gabbas; P Foa; A Locasciulli; C Rosanelli; L Camba; P Saracco; A Lippi; A P Iori; F Porta; G De Rossi; B Comotti; P Iacopino; C Dufour; A Bacigalupo; V De Rossi
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

6.  A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders.

Authors:  Vikas Gupta; Edward C Gordon-Smith; Gordon Cook; Anne Parker; Jennifer K M Duguid; Keith M O Wilson; Qi-Long Yi; Judith C W Marsh
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

7.  Allogeneic hematopoietic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia--a single-center analysis of 100 patients.

Authors:  Biju George; Vikram Mathews; Auro Viswabandya; Kavitha M Lakshmi; Alok Srivastava; Mammen Chandy
Journal:  Pediatr Hematol Oncol       Date:  2010-03       Impact factor: 1.969

8.  Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.

Authors:  S Kojima; S Hibi; Y Kosaka; M Yamamoto; M Tsuchida; H Mugishima; K Sugita; H Yabe; A Ohara; I Tsukimoto
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

9.  Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study.

Authors: 
Journal:  Blood       Date:  1987-12       Impact factor: 22.113

10.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

View more
  3 in total

1.  Epidemiological Features of Aplastic Anemia in Indian Children.

Authors:  Vineeta Gupta; Raghvendra Pratap; Akash Kumar; Isha Saini; Jyoti Shukla
Journal:  Indian J Pediatr       Date:  2013-10-10       Impact factor: 1.967

2.  Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia.

Authors:  M B Agarwal; Farah Jijina; Sandip Shah; Pankaj Malhotra; Sharat Damodar; Cecil Ross
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-16       Impact factor: 0.900

3.  Response to Horse ATG (Thymogam, Bharat Serums and Vaccine, India) and Cyclosporine in Aplastic Anemia: A Single Centre, Retrospective Study of 60 Patients from Southern India.

Authors:  Deepak S Amalnath
Journal:  Indian J Hematol Blood Transfus       Date:  2019-05-20       Impact factor: 0.900

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.